Stock Research for ESPR

ESPR

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ESPR Stock Chart & Research Data

The ESPR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ESPR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ESPR Due diligence Resources & Stock Charts

The ESPR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ESPR Detailed Price Forecast - CNN Money CNN View ESPR Detailed Summary - Google Finance
Yahoo View ESPR Detailed Summary - Yahoo! Finance Zacks View ESPR Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ESPR Trends & Analysis - Trade-Ideas Barrons View ESPR Major Holders - Barrons
NASDAQ View ESPR Call Transcripts - NASDAQ Seeking View ESPR Breaking News & Analysis - Seeking Alpha
Spotlight View ESPR Annual Report - CompanySpotlight.com OTC Report View ESPR OTC Short Report - OTCShortReport.com
TradeKing View ESPR Fundamentals - TradeKing Charts View ESPR SEC Filings - Bar Chart
WSJ View Historical Prices for ESPR - The WSJ Morningstar View Performance/Total Return for ESPR - Morningstar
MarketWatch View the Analyst Estimates for ESPR - MarketWatch CNBC View the Earnings History for ESPR - CNBC
StockMarketWatch View the ESPR Earnings - StockMarketWatch MacroAxis View ESPR Buy or Sell Recommendations - MacroAxis
Bullish View the ESPR Bullish Patterns - American Bulls Short Pains View ESPR Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ESPR Stock Mentions - StockTwits PennyStocks View ESPR Stock Mentions - PennyStockTweets
Twitter View ESPR Stock Mentions - Twitter Invest Hub View ESPR Investment Forum News - Investor Hub
Yahoo View ESPR Stock Mentions - Yahoo! Message Board Seeking Alpha View ESPR Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ESPR - SECform4.com Insider Cow View Insider Transactions for ESPR - Insider Cow
CNBC View ESPR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ESPR - OTC Markets
Yahoo View Insider Transactions for ESPR - Yahoo! Finance NASDAQ View Institutional Holdings for ESPR - NASDAQ


Stock Charts

FinViz View ESPR Stock Insight & Charts - FinViz.com StockCharts View ESPR Investment Charts - StockCharts.com
BarChart View ESPR Stock Overview & Charts - BarChart Trading View View ESPR User Generated Charts - Trading View


Latest Financial News for ESPR

ESPR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of July 6, 2018
Posted on Tuesday May 22, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. ("Esperion") (ESPR) securities between February 22, 2017 and May 1, 2018. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.


Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Esperion Therapeutics, Inc.
Posted on Tuesday May 22, 2018

The law firm of Kessler Topaz Meltzer & Check, LLP announces that an investor class action lawsuit has been filed against Esperion Therapeutics, Inc. (ESPR) (“Esperion”) on behalf of purchasers of Esperion securities between February 22, 2017 and May 1, 2018, inclusive (the “Class Period”). Esperion investors who purchased securities during the Class Period may, no later than July 6, 2018, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, Esperion is a biopharmaceutical company that is primarily focused on the research and development of oral and small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors.


Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
Posted on Tuesday May 22, 2018

Esperion (ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat with investors at the UBS Global Healthcare Conference in New York, NY on Wednesday, May 23, 2018, at 10:30 a.m. Eastern Time. A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com. Through the complementary mechanisms of action of inhibition of cholesterol synthesis (bempedoic acid) and inhibition of cholesterol absorption (ezetimibe), the bempedoic acid / ezetimibe combination pill is our lead, non-statin, orally available, once-daily, LDL-C lowering therapy.


SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ESPR
Posted on Saturday May 19, 2018

NEW YORK, NY / ACCESSWIRE / May 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Esperion Therapeutics, Inc. ("Esperion" or the "Company") (ESPR) and certain of its officers. The class action, filed in United States District Court, Eastern District of Michigan, and docketed under 18-cv-11438, is on behalf of a class consisting of investors who purchased or otherwise acquired Esperion securities between February 22, 2017 and May 1, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.


Enter a stock symbol to view the stock details.